Stéphane Jacquot

488 total citations
13 papers, 185 citations indexed

About

Stéphane Jacquot is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stéphane Jacquot has authored 13 papers receiving a total of 185 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Hepatology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stéphane Jacquot's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Stéphane Jacquot is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Stéphane Jacquot collaborates with scholars based in France, United States and India. Stéphane Jacquot's co-authors include Renaud Fay, S. Giard, H. Auvray, C. Lemanski, C. Charra-Brunaud, V. Servent, B. De Lafontan, H. Mignotte, B. Cutuli and Éric François and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Stéphane Jacquot

13 papers receiving 178 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stéphane Jacquot France	4	109	103	87	35	34	13	185
Kai-Keen Shiu United Kingdom	3	153 1.4×	51 0.5×	64 0.7×	34 1.0×	37 1.1×	4	207
Shu-Lian Wang China	4	155 1.4×	106 1.0×	52 0.6×	21 0.6×	39 1.1×	6	230
Ajlan Atasoy Belgium	8	199 1.8×	53 0.5×	55 0.6×	70 2.0×	79 2.3×	17	261
Daniela Gianquinto Italy	8	262 2.4×	58 0.6×	62 0.7×	69 2.0×	71 2.1×	13	312
Simona Di Lascio Switzerland	7	114 1.0×	56 0.5×	22 0.3×	40 1.1×	53 1.6×	15	171
Ondřej Májek Czechia	4	167 1.5×	20 0.2×	83 1.0×	36 1.0×	57 1.7×	16	223
Carolin Nestle-Krämling Germany	8	102 0.9×	165 1.6×	77 0.9×	62 1.8×	27 0.8×	14	258
F. Losa Gaspà Spain	4	136 1.2×	35 0.3×	60 0.7×	23 0.7×	62 1.8×	9	188
Edith Perez United States	3	122 1.1×	89 0.9×	43 0.5×	20 0.6×	100 2.9×	3	214
Susanne Markmann Germany	8	120 1.1×	138 1.3×	63 0.7×	56 1.6×	39 1.1×	23	305

Countries citing papers authored by Stéphane Jacquot

Since Specialization

Citations

This map shows the geographic impact of Stéphane Jacquot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Jacquot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Jacquot more than expected).

Fields of papers citing papers by Stéphane Jacquot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Jacquot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Jacquot. The network helps show where Stéphane Jacquot may publish in the future.

Co-authorship network of co-authors of Stéphane Jacquot

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Jacquot. A scholar is included among the top collaborators of Stéphane Jacquot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Jacquot. Stéphane Jacquot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Jacquot, Stéphane, et al.. (2023). Breast Cancer: How Hippotherapy Bridges the Gap between Healing and Recovery—A Randomized Controlled Clinical Trial. Cancers. 15(4). 1317–1317. 3 indexed citations

Fabre, Aurélie, Karine Le Malicot, Jaafar Bennouna, et al.. (2022). Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. Therapeutic Advances in Medical Oncology. 14. 4287553339–4287553339. 3 indexed citations

Aparicio, Thomas, François Ghiringhelli, Valérie Boige, et al.. (2018). Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). Journal of Clinical Oncology. 36(7). 674–681. 59 indexed citations

Samalin, Emmanuelle, Hélène Senellart, Simon Thézenas, et al.. (2017). Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v179–v179. 1 indexed citations

Dohan, Anthony, B. Gallix, Boris Guiu, et al.. (2017). Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).. Journal of Clinical Oncology. 35(15_suppl). 3601–3601. 1 indexed citations

Ganem, G., Éric-Charles Antoine, Chantal Touboul, et al.. (2016). Maintaining professional activity during breast cancer treatment. European Journal of Cancer Care. 25(3). 458–465. 7 indexed citations

Aparicio, Thomas, Jaafar Bennouna, Karine Le Malicot, et al.. (2016). Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). 3531–3531. 7 indexed citations

Fabre, Aurélie, Thomas Aparicio, Karine Le Malicot, et al.. (2016). Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.. Journal of Clinical Oncology. 34(15_suppl). 3534–3534. 2 indexed citations

Aparicio, Thomas, Jaafar Bennouna, Karine Le Malicot, et al.. (2014). Interim Analysis of Prodige 9, a Randomized Phase III Trial Comparing No Treatment to Bevacizumab Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer. Annals of Oncology. 25. iv171–iv171. 2 indexed citations

10.

Ganem, G., H. Naman, Nadine Dohollou, et al.. (2013). Continuing to work while receiving cancer treatment: A financial or a symbolic issue?. Journal of Clinical Oncology. 31(15_suppl). 6603–6603. 1 indexed citations

11.

Jacquot, Stéphane, et al.. (2012). La justice réparatrice : quand victimes et coupables échangent pour limiter la récidive. Medical Entomology and Zoology. 1 indexed citations

12.

Cutuli, B., B. De Lafontan, H. Mignotte, et al.. (2002). Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience. International Journal of Radiation Oncology*Biology*Physics. 53(4). 868–879. 96 indexed citations

13.

Jacquot, Stéphane, et al.. (1989). Nécrose gastrique après un accès boulimique chez une anorexique. La Presse Médicale. 18(39). 1932–1932. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact